|Systematic (IUPAC) name|
|Molecular mass||215.3339 g/mol|
|(what is this?)|
8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s. It is a structural analog of Phencyclidine with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.
- US Patent 3035059
- Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP (1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871.
- Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC (2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". J Mol Model 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600.
|This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it.|